基金二季报藏大招：AI、核聚变被狂买，北交所火了

Core Insights - The second quarter saw explosive growth in several fund products, with some "mini funds" experiencing remarkable reversals, notably the Changcheng Medical Industry Selected Mixed Fund, which surged from 0.36 billion to 11.32 billion, a growth of over 30 times [1][2] - Fund managers adopted a more aggressive approach in a volatile market, increasing equity positions and significantly adjusting their heavy holdings, focusing on cutting-edge technology sectors such as artificial intelligence computing, innovative pharmaceuticals, and controllable nuclear fusion [1][3] Fund Performance - The Changcheng Fund's products stood out, with the Changcheng Medical Industry Selected Mixed Fund achieving over 30 times growth, while the Changcheng Prosperity Growth Mixed Fund increased from 0.7 billion to 3.2 billion [2] - The Zhongou Fund also saw significant increases, with the Zhongou Digital Economy Mixed Fund's A-class shares exceeding 220 million subscriptions, and the total fund size growing from less than 800 million to over 9 billion, a more than 10-fold increase [2] - The Zhongou Information Technology Mixed Fund's total subscriptions surpassed 900 million, with a total size exceeding 1 billion, growing over 8 times from the previous quarter [2] Portfolio Adjustments - Fund managers generally opted for aggressive strategies, with the Changcheng Medical Industry Selected Mixed Fund increasing its equity position from 72.48% to 75.89%, focusing on the innovative pharmaceutical sector [3] - The Yongying Fund's products underwent significant portfolio changes, with the Yongying Technology Selected Fund completely renewing its top ten heavy holdings, including companies like Xinyi Technology and Zhongji Xuchuang [3][4] Strategic Focus Areas - Fund managers are strategically focusing on cutting-edge technology sectors, particularly artificial intelligence computing, which is gaining attention due to the increasing demand for model/application and computing power investments [5] - The innovative pharmaceutical sector is expected to undergo a value reassessment, with managers identifying high-potential companies in niche areas for early investment [6] - Controllable nuclear fusion is attracting strategic bets, with funds focusing on companies within the nuclear fusion supply chain, anticipating significant revenue potential despite the technology's current stage [6] Emerging Investment Trends - The Beijing Stock Exchange has become a new hotspot for fund establishment, with new funds rapidly completing high-position layouts, indicating increased institutional participation in small and medium-sized growth enterprises [7]